PriceTargets.com logo

Chembio Diagnostics - CEMI Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.46 As of 04/27/2023 01:00 AM ET
+0 (0.00%)
Get New Chembio Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CEMI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CEMI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Chembio Diagnostics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.46.

This chart shows the closing price for CEMI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Chembio Diagnostics. This rating has held steady since February 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/22/2022Colliers SecuritiesReiterated RatingNeutral
7/21/2021Colliers SecuritiesDowngradeBuy ➝ Neutral
3/11/2021Colliers SecuritiesReiterated RatingBuy$8.00
12/3/2020Craig HallumUpgradeHold ➝ Buy$5.00 ➝ $10.00
11/6/2020Colliers SecuritiesUpgradeNeutral ➝ Buy$7.50
6/17/2020Robert W. BairdDowngradeHold$4.00
6/17/2020Colliers SecuritiesDowngradeBuy ➝ Neutral
6/17/2020Craig HallumDowngradeBuy ➝ Hold$8.00
6/17/2020BenchmarkDowngradeSpeculative Buy ➝ Hold
5/26/2020Robert W. BairdInitiated CoverageOutperform$21.00
4/23/2020Craig HallumBoost TargetBuy$15.00 ➝ $21.00
4/1/2020BenchmarkBoost TargetSpeculative Buy$4.00 ➝ $7.00
3/4/2020BenchmarkLower TargetSpeculative Buy$9.00 ➝ $5.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Chembio Diagnostics logo
Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.
Read More

Today's Range

Now: $0.46
Low: $0.45
High: $0.46

50 Day Range

MA: $0.43
Low: $0.33
High: $0.46

52 Week Range

Now: $0.46
Low: $0.19
High: $1.24

Volume

351,642 shs

Average Volume

661,416 shs

Market Capitalization

$16.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Chembio Diagnostics?

The following equities research analysts have issued research reports on Chembio Diagnostics in the last twelve months: StockNews.com.
View the latest analyst ratings for CEMI.

What is the current price target for Chembio Diagnostics?

0 Wall Street analysts have set twelve-month price targets for Chembio Diagnostics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Chembio Diagnostics in the next year.
View the latest price targets for CEMI.

What is the current consensus analyst rating for Chembio Diagnostics?

Chembio Diagnostics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CEMI.

What other companies compete with Chembio Diagnostics?

Other companies that are similar to Chembio Diagnostics include Tonix Pharmaceuticals, Virios Therapeutics, Viveon Health Acquisition, Prelude Therapeutics and InterCure. Learn More about companies similar to Chembio Diagnostics.

How do I contact Chembio Diagnostics' investor relations team?

Chembio Diagnostics' physical mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company's listed phone number is (631) 924-1135 and its investor relations email address is [email protected]. The official website for Chembio Diagnostics is www.chembio.com. Learn More about contacing Chembio Diagnostics investor relations.